Thomas Evers
YOU?
Author Swipe
View article: Patient Perspectives on the Burden of Heart Failure with Preserved Ejection Fraction in a US Commercially Insured and Medicare Advantage Population: A Survey Study
Patient Perspectives on the Burden of Heart Failure with Preserved Ejection Fraction in a US Commercially Insured and Medicare Advantage Population: A Survey Study Open
Patient-reported outcome measure scores indicated impairment due to HF symptoms and physical limitations in this real-world sample of patients with HFpEF, highlighting a need to assess patient-reported outcomes as well as the clinical and …
View article: Predictive Risk Models to Identify Patients at High-Risk for Severe Clinical Outcomes With Chronic Kidney Disease and Type 2 Diabetes
Predictive Risk Models to Identify Patients at High-Risk for Severe Clinical Outcomes With Chronic Kidney Disease and Type 2 Diabetes Open
Introduction/Objective: Predictive risk models identifying patients at high risk for specific outcomes may provide valuable insights to providers and payers regarding points of intervention and modifiable factors. The goal of our study was…
View article: POS-345 ASSOCIATION BETWEEN RELATIVE ESTIMATED GLOMERULAR FILTRATION RATE CHANGES AND DAYS OUT OF THE HOME AND COST OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES
POS-345 ASSOCIATION BETWEEN RELATIVE ESTIMATED GLOMERULAR FILTRATION RATE CHANGES AND DAYS OUT OF THE HOME AND COST OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES Open
A ≥40% relative decline in estimated glomerular filtration rate (eGFR) has been supported for use as a surrogate endpoint for clinical outcomes. However, the associations between this change and resulting days that a patient spends out of …
View article: POS-344 ASSOCIATION BETWEEN RELATIVE ESTIMATED GLOMERULAR FILTRATION RATE CHANGES AND CLINICAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES
POS-344 ASSOCIATION BETWEEN RELATIVE ESTIMATED GLOMERULAR FILTRATION RATE CHANGES AND CLINICAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES Open
Research supporting the validity of changes in estimated glomerular filtration rate (eGFR) as a surrogate endpoint for end-stage kidney disease (ESKD) or other clinical outcomes in patients with type 2 diabetes mellitus (T2DM) is limited. …
View article: Adherence to Chronic Kidney Disease Screening Guidelines Among Patients With Type 2 Diabetes in a US Administrative Claims Database
Adherence to Chronic Kidney Disease Screening Guidelines Among Patients With Type 2 Diabetes in a US Administrative Claims Database Open
Physicians treating patients with diabetes are selectively adhering to chronic kidney disease screening guidelines, as indicated by high rates of eGFR testing, but less frequent UACR testing. Despite recommendations to monitor both eGFR an…
View article: Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs for Patients with Newly Diagnosed Systolic versus Diastolic Heart Failure.
Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs for Patients with Newly Diagnosed Systolic versus Diastolic Heart Failure. Open
This real-world analysis confirms a high disease burden associated with HF and provides insight across the systolic HF and diastolic HF phenotypes. HF-related medication use after diagnosis was suboptimal and underscores a gap in patient c…
View article: Using Real-World Data to Predict Clinical and Economic Benefits of a Future Drug Based on its Target Product Profile
Using Real-World Data to Predict Clinical and Economic Benefits of a Future Drug Based on its Target Product Profile Open
We present a simple approach to assess the potential absolute clinical and economic benefit of a new drug based on real-world data and its target product profile. The approach allows for early data-driven portfolio decisions to select drug…
View article: <p>Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model</p>
Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model Open
These findings of heterogeneous relationships between several important risk factors and heart failure types underline the potential differences in the etiology of HFpEF and HFrEF.
View article: Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model
Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model Open
Moa P Lee,1,2 Robert J Glynn,1 Sebastian Schneeweiss,1 Kueiyu Joshua Lin,1,3 Elisabetta Patorno,1 Julie Barberio,1 Raisa Levin,1 Thomas Evers,4 Shirley V Wang,1 Rishi J Desai1 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigha…
View article: Economic burden of coronary artery disease or peripheral artery disease in patients at high risk of ischemic events in the French setting: a claims database analysis
Economic burden of coronary artery disease or peripheral artery disease in patients at high risk of ischemic events in the French setting: a claims database analysis Open
Aims: Estimate the direct costs of high-risk patients presenting with coronary artery disease (CAD) or peripheral artery disease (PAD) in France.Materials and methods: This retrospective cohort study used a representative claims database, …
View article: Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes Open
Machine learning methods offered only limited improvement over traditional logistic regression in predicting key HF outcomes. Inclusion of additional predictors from EMRs to claims-based models appeared to improve prediction for some, but …
View article: Risk factors for heart failure with preserved or reduced ejection fraction among Medicare beneficiaries: Applications of competing risks analysis and gradient boosted model
Risk factors for heart failure with preserved or reduced ejection fraction among Medicare beneficiaries: Applications of competing risks analysis and gradient boosted model Open
Background The differential impact of various demographic characteristics and comorbid conditions on development of heart failure (HF) with preserved (pEF) and reduced ejection fraction (rEF) is not well studied among the elderly. Methods …
View article: Complexe sleep apnea as a challenge for hypoglossal nerve stimulation
Complexe sleep apnea as a challenge for hypoglossal nerve stimulation Open
A 52 year old male patient was referred to our hospital with persistent daytime sleepiness. An external sleep laboratory had diagnosed obstructive sleep apnea and used continuous positive airway pressure as first-line therapy. The patient …
View article: Using Real‐World Data to Extrapolate Evidence From Randomized Controlled Trials
Using Real‐World Data to Extrapolate Evidence From Randomized Controlled Trials Open
Randomized controlled trials (RCTs) provide evidence for regulatory agencies, shape clinical practice, influence formulary decisions, and have important implications for patients. However, many patient groups that are major consumers of dr…
View article: Iceberg tumor leading to obstructive sleep apnea?
Iceberg tumor leading to obstructive sleep apnea? Open
A 53 year old patient was referred to our outpatient department with a massive tumor at the right soft palate. Two months before CPAP-therapy was initiated due to a severe obstructive sleep apnea with significant daytime tiredness. Difficu…
View article: Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS‐ACTS Substudy
Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS‐ACTS Substudy Open
Background The efficacy, safety, and ease of use of rivaroxaban may reduce anticoagulation‐treatment burden and improve nonvalvular atrial fibrillation (NVAF) patient satisfaction compared with vitamin K antagonists (VKAs). Hypothesis Tran…
View article: Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States
Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States Open
A retrospective cohort analysis of the US MarketScan claims databases was performed to compare persistence and discontinuation rates between the vitamin K antagonist warfarin and the non-vitamin K antagonist oral anticoagulants rivaroxaban…
View article: Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain
Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain Open
Objective: The aim of this study was to evaluate, from the Spanish National Health System perspective, the cost-effectiveness of rivaroxaban (20 mg/day) versus use of acenocoumarol (5 mg/day) for the treatment of patients with non-valvular…
View article: Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation
Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation Open
Rivaroxaban and dabigatran demonstrated better persistence than VKA at Day 360. Furthermore, rivaroxaban was associated with better persistence and adherence than dabigatran. Further studies are needed to identify factors responsible for t…
View article: Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a<i>post hoc</i>analysis of the X-VeRT trial
Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a<i>post hoc</i>analysis of the X-VeRT trial Open
The use of rivaroxaban in the setting of cardioversion resulted in greater patient satisfaction and cost savings, compared with that of VKA.
View article: REal-LIfe Evidence of stroke prevention in patients with atrial Fibrillation — The RELIEF study
REal-LIfe Evidence of stroke prevention in patients with atrial Fibrillation — The RELIEF study Open
Rivaroxaban has been shown effective in reducing the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) in a randomized controlled trial (RCT) [[1]Patel M.R. Mahaffey K.W. Garg J. Pan G. Singer D.E. Hacke W. Breithardt…